GPRC5D-targeting bispecific antibody

GPRC5D-targeting bispecific antibodies represent a novel class of T-cell engaging immunotherapies primarily developed for the treatment of relapsed or refractory multiple myeloma. These agents are designed with dual binding specificity: one arm targets the G protein-coupled receptor class C group 5 member D (GPRC5D), an orphan receptor highly and selectively expressed on malignant plasma cells, while the other arm binds to the CD3 epsilon subunit of the T-cell receptor complex. By physically bridging cytotoxic T cells to myeloma cells, these antibodies induce T-cell activation, degranulation, and subsequent lysis of the tumor cells, bypassing the need for major histocompatibility complex (MHC) class I recognition. Talquetamab (Talvey) was the first-in-class agent in this category to receive regulatory approval, offering a therapeutic alternative for patients who have exhausted other options, including BCMA-targeted therapies.

Brand names

Talvey

Other names

GPRC5D x CD3 bispecific antibodyGPRC-5D x CD3 bispecific antibodyGPRC 5D x CD3 bispecific antibodyGPRC5D-targeting T-cell engagerGPRC-5D-targeting T-cell engagerGPRC 5D-targeting T-cell engagertalquetamabforimtamig